Ask AI
ProCE Banner Activity

Phase II DEBBRAH: Trastuzumab Deruxtecan in Cohort With HER2+/HER-Low ABC and Leptomeningeal Carcinomatosis

Conference Coverage
Slideset

This analysis of a small cohort from the phase II DEBBRAH trial met its primary endpoint of overall survival in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis treated with trastuzumab deruxtecan.

Released: December 09, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.